Peer-reviewedCC BY-NC-NDInternal Medicine
Immune Checkpoint Inhibitor Therapy Triggers Autoimmune Cerebellar Ataxia with Anti-P/Q-type VGCC Antibody and Anti-mGluR5 Antibodies: A Case Report
Abstract
Autoimmune cerebellar ataxia (ACA) is an immune-mediated cerebellar syndrome that is often associated with specific autoantibodies. We report a case of a 61-year-old man with small cell lung cancer who developed subacute progressive cerebellar ataxia after durvalumab therapy. Anti-P/Q-type voltage-gated calcium channel (VGCC) and anti-metabotropic glutamate receptor 5 (mGluR5) antibodies were detected. The patient improved substantially with early immunotherapy and the discontinuation of immune checkpoint inhibitor (ICIs) therapy. In this case, anti-VGCC antibodies may have contributed to the pathophysiology. However, anti-mGluR5 antibodies were also detected. The relationship between ACA and ICIs therapy remains unclear, and additional cases are needed.
Related
- Immune Checkpoint Inhibitor-Related Hepatitis Versus Classical Autoimmune Hepatitis: A Retrospective Multidomain Phenotype Comparison
- Immune Checkpoint Inhibitor Data in Metastatic Melanoma with Pre-Existing Autoimmune Disease: A Real World Experience
- Risk of de novo immune-related adverse events in patients with cancer and autoimmune disease receiving immune checkpoint inhibitors
- Association between rituximab treatment and outcome in nonparaneoplastic autoimmune cerebellar ataxia: an observational cohort study
- IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity
BibTeX
@article{nakamura2026immune,
title = {{Immune Checkpoint Inhibitor Therapy Triggers Autoimmune Cerebellar Ataxia with Anti-P/Q-type VGCC Antibody and Anti-mGluR5 Antibodies: A Case Report}},
author = {Shuntaro Nakamura and Kazuki Yamada and Hiroaki Yaguchi and Akihiko Kudo and Shintaro Fujii and Taichi Nomura and Shoki Sato and Taishi Iwanami and Kaiki Kawakita and Hanko Sato and Keita Majima and Kei Oiwa and Kosuke Iwami and Daiki Tanaka and Katsuki Eguchi and Hisashi Uwatoko and Shinichi Shirai and Ikuko Takahashi-Iwata and Masaaki Matsushima and Doppo Fukui and Megumi Furuta and Fumitaka Shimizu and Keiko Tanaka and Satoshi Konno and Ichiro Yabe},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.7680-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7680-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Immune Checkpoint Inhibitor Therapy Triggers Autoimmune Cerebellar Ataxia with Anti-P/Q-type VGCC Antibody and Anti-mGluR5 Antibodies: A Case Report
AU - Shuntaro Nakamura
AU - Kazuki Yamada
AU - Hiroaki Yaguchi
AU - Akihiko Kudo
AU - Shintaro Fujii
AU - Taichi Nomura
AU - Shoki Sato
AU - Taishi Iwanami
AU - Kaiki Kawakita
AU - Hanko Sato
AU - Keita Majima
AU - Kei Oiwa
AU - Kosuke Iwami
AU - Daiki Tanaka
AU - Katsuki Eguchi
AU - Hisashi Uwatoko
AU - Shinichi Shirai
AU - Ikuko Takahashi-Iwata
AU - Masaaki Matsushima
AU - Doppo Fukui
AU - Megumi Furuta
AU - Fumitaka Shimizu
AU - Keiko Tanaka
AU - Satoshi Konno
AU - Ichiro Yabe
PY - 2026
DA - 2026/09/29
JO - Internal Medicine
DO - 10.2169/internalmedicine.7680-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7680-26/_article
AB - Autoimmune cerebellar ataxia (ACA) is an immune-mediated cerebellar syndrome that is often associated with specific autoantibodies. We report a case of a 61-year-old man with small cell lung cancer who developed subacute progressive cerebellar ataxia after durvalumab therapy. Anti-P/Q-type voltage-gated calcium channel (VGCC) and anti-metabotropic glutamate receptor 5 (mGluR5) antibodies were detected. The patient improved substantially with early immunotherapy and the discontinuation of immune checkpoint inhibitor (ICIs) therapy. In this case, anti-VGCC antibodies may have contributed to the pathophysiology. However, anti-mGluR5 antibodies were also detected. The relationship between ACA and ICIs therapy remains unclear, and additional cases are needed.
SN - 1349-7235
SN - 0918-2918
ER -